

APR 19, 2023

# OPEN BACCESS

**Protocol Citation:** Katrina M Pollock, Calliope Dendrou 2023. LEGACY01: STUDY MANAGEMENT. **protocols.io** https://protocols.io/view/legacy01-study-management-cmkcu4sw

License: This is an open access protocol distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working We use this protocol and it's working

Created: Jan 11, 2023

Last Modified: Apr 19, 2023

## **PROTOCOL integer ID:** 75108

**Keywords:** Single-cell sequencing, lymph node, influenza vaccine, ancestry

## ← LEGACY01: STUDY MANAGEMENT

In 1 collection

## Katrina M Pollock<sup>1</sup>, Calliope Dendrou<sup>2</sup>

<sup>1</sup>NIHR Imperial Clinical Research Facility, ICTEM Building, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, UK; <sup>2</sup>Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN

Katrina M Pollock: Chief Investigator; Calliope Dendrou: Scientific Lead

### Human Cell Atlas Method Development Community



Katrina M Pollock
University of Oxford , Imperial College London

DISCLAIMER

# DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

### **ABSTRACT**

This protocol details study management in an experimental medicine study of seasonal influenza vaccination responses in Lymph nodE single-cell Genomics in AnCestrY (LEGACY01).

**ATTACHMENTS** 

602-1266.docx

#### STUDY MANAGEMENT

The day-to-day management of the study will be co-ordinated through NIHR Imperial CRF and the study manager Aime Palomeras.

### LABORATORY DATA RECORDING AND MONITORING

Laboratory data management for the study will be co-ordinated by Calli Dendrou, Brian Marsden and Teresa Lambe at the University of Oxford. Data will be stored with linked anonymised (pseudonymised) codes, and all files and databases will be password protected and held on password protected computers. Pseudanonymised identifiers will be kept on a secured NHS workstation at NIHR Imperial CRF before transfer of the minimally required demographic metadata (e.g. sex and age) to study scientists in Oxford.

Raw and analysed sequencing, genetic, flow cytometric and serological data will be collated and stored on a restricted access site on a University of Oxford computational cluster (BMRC) and will be managed and curated according to established protocols. The storage system of the computational cluster is resilient to disk failure and data are automatically backed up to linked off-site servers. Data files will be clearly labelled and associated (cleaned and anonymised) metadata will be stored in tab-delimited text files so as to document the provenance of the data. Where automated analyses are performed, these will be version controlled and the commands used will be recorded in log files. Data arising from smaller-scale laboratory analyses will be recorded in hard copy or electronic laboratory notebooks according to standard University practices. Data (and analysis scripts) will be maintained in this way for ten years after study completion.

### PROJECT MANAGEMENT AND GOVERNANCE

Imperial College London and University of Oxford are the principal partners for delivery of the study in the UK. These two institutions will partner with Uganda Virus Research Institute (UVRI), who will be responsible for international capacity building to undertake future single-cell and lymphatic tissue focussed vaccine research under the umbrella of the LEGACY Network.